
CheckMate 238
NCT02388906
JCP001
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)
Status:
Closed to Accrual

III
Phase

Adjuvant
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
PD-1, PD-L1
Investigational
Product
Nivolumab
Treatment Arms
o Ipilimumab and Placebo matching Nivolumab
o Nivolumab and Placebo matching Ipilimumab